New Antiangiogenetic Therapy Beyond Bevacizumab in the Treatment of Advanced Non Small Cell Lung Cancer

E-ISSN： 1873-4286|21|32|4763-4772

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.21, Iss.32, 2015-10, pp. : 4763-4772

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Bevacizumab: a potential new option in the treatment of advanced breast or non-small-cell lung cancer

By Adis International Limited

Drugs & Therapy Perspectives, Vol. 22, Iss. 9, 2006-09 ,pp. : 1-4

Adis International

Access to resources Recommend Favorite

Bevacizumab as First-Line Therapy in Advanced Non-Small-Cell Lung Cancer: A Brazilian Center Experience

By > > > > Katz Artur

Drugs in R&D, Vol. 12, Iss. 4, 2012-12 ,pp. : 207-216

Adis International

Access to resources Recommend Favorite

Bowel perforation in non-small cell lung cancer after bevacizumab therapy

By Schellhaas Elisabeth Loddenkemper Christoph Schmittel Alexander Buhr Heinz-J. Pohlen Uwe

Investigational New Drugs, Vol. 27, Iss. 2, 2009-04 ,pp. : 184-187

Springer Publishing Company

Access to resources Recommend Favorite

Dacomitinib, a new therapy for the treatment of non-small cell lung cancer

By Brzezniak Christina Carter Corey A Giaccone Giuseppe

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 2, 2013-02 ,pp. : 247-253

Informa Healthcare

Access to resources Recommend Favorite

Bevacizumab in Non-Small Cell Lung Cancer

By Francesco Di Costanzo

Drugs, Vol. 68, Iss. 6, 2008-01 ,pp. : 737-746

Adis International

Access to resources Recommend Favorite